Small-Molecule Degradation of the MicroRNA-21 Precursor Rescues Pathogenic Pathways in Cellular Models of Fibrosis.

Area of Science:

• Molecular Biology
• RNA Therapeutics
• Disease Pathology

Background:

• MicroRNAs (miRNAs) regulate gene expression; miR-21 overexpression is linked to diseases like ADPKD and pulmonary fibrosis.
• Autosomal dominant polycystic kidney disease (ADPKD) and pulmonary fibrosis are debilitating conditions with limited therapeutic options.

Purpose of the Study:

• To investigate the efficacy of the heterobifunctional molecule TGP-21-RiboTAC in degrading miR-21 precursors.
• To evaluate the therapeutic potential of TGP-21-RiboTAC in preclinical models of ADPKD and pulmonary fibrosis.

Main Methods:

• TGP-21-RiboTAC was tested in polycystic kidney cell lines and a lung fibroblast cell line (MRC-5).
• Degradation of pre-miR-21 and mature miR-21 levels were assessed.
• Downstream targets of miR-21, including PDCD4, PPARα, and SMAD7, were analyzed.
• Effects on cyst growth, metabolic alterations, and cell invasion were evaluated.

Main Results:

• TGP-21-RiboTAC successfully degraded pre-miR-21 in kidney cells, leading to derepression of PDCD4 and PPARα, key drivers of ADPKD.
• The molecule inhibited cyst growth and corrected metabolic abnormalities in ADPKD models.
• In lung fibroblasts, TGP-21-RiboTAC reduced miR-21 levels, rescued TGF-β-induced SMAD7 repression, and inhibited cell invasion.

Conclusions:

• Targeted RNA degradation using molecules like TGP-21-RiboTAC is a viable therapeutic strategy.
• This approach shows potential for retarding the development of organ fibrosis in diseases such as ADPKD and pulmonary fibrosis.